The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 16, 2021

Filed:

Apr. 07, 2017
Applicant:

The Administrators of the Tulane Educational Fund, New Orleans, LA (US);

Inventors:

Stephen E. Braun, New Orleans, LA (US);

Reza Izadpanah, New Orleans, LA (US);

Eckhard Alt, New Orleans, LA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/35 (2015.01); C12N 15/113 (2010.01); A61K 9/00 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
A61K 35/35 (2013.01); A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); C12N 15/1138 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01);
Abstract

A method of curing (or at least treating) HIV, by obtaining small tissue mesenchymal stem cells (stMSC) from adipose tissue of a patient with HIV or from a syngeneic donor or an immuno-compatible donor, wherein said stMSC are i) 4-6 μm in diameter, ii) pluripotent, and iii) have CD11b, CD34, CD45, CD 29, CD 49, Oct 4 and SSEA 4 surface markers when harvested. Preferred sources are autologous adipose tissue. Next those stMSCs are gene edited to provide CCR5stMSCs and optionally amplified by growth in culture and/or by cell selection for gene edited stMSCs and then re-introducing into the patient. Preferably, the CCR5stMSCs will re-populate the patient with stem cells that can no longer act as latent HIV reservoirs and can differentiate into immune cells that are HIV resistant. If desired, the patient can be first treated, e.g., by radiation, to destroy the bone marrow cells before the re-introduction. However, this may not be necessary for patient who already has significant destruction of immunity by HIV.


Find Patent Forward Citations

Loading…